CLAIMS

1. A dosage form comprising a complex of meloxicam and a sulfobutyl ether β-cyclodextrin (SBEβCD), and a bicarbonate, wherein the dosage form is a solid oral dosage form containing 400 mg to 1000 mg of the bicarbonate and having a shorter T_{max} of meloxicam when administered to a human being than a reference dosage form that: 1) contains the same amount of meloxicam, 2) does not contain an SBEβCD, and 3) does not contain a bicarbonate.

2. The dosage form of claim 1, wherein the SBEβCD has about 6 to about 7 sulfobutyl ether groups for each molecule of β-cyclodextrin.

3. The dosage form of claim 1 or 2, wherein the meloxicam and the SBEβCD have a molar ratio of about 0.8 to about 1.2.

4. The dosage form of claim 3, wherein the meloxicam and the SBEβCD have a molar ratio of about 1.

5. The dosage form of claim 1, 2, 3, or 4, wherein the bicarbonate comprises sodium bicarbonate.

6. The dosage form of claim 1, 2, 3, 4, or 5, wherein the complex comprises an inclusion complex of the meloxicam and cyclodextrin, and about 50 mg to about 200 mg of SBEβCD is present in the dosage form.

7. The dosage form of claim 1, 2, 3, 4, 5, or 6, wherein the bicarbonate is present in an amount of 400 mg to 600 mg.

8. The dosage form of claim 7, wherein the bicarbonate is sodium bicarbonate.

9. The dosage form of claim 1, 2, 3, 4, 5, 6, 7, or 8, further comprising an acid inhibitor.

10. The dosage form of claim 9, wherein the acid inhibitor is a proton pump inhibitor.

11. The dosage form of claim 10, wherein the proton pump inhibitor is esomeprazole, omeprazole, lansoprazole, pantoprazole, or rabeprazole.

12. The dosage form of claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11, wherein oral administration of the dosage form to the human being results in a T_{max} of meloxicam that is between 10 minutes and 180 minutes after administration.

13. The dosage form of claim 11, wherein about 30 mg to about 50 mg of esomeprazole is present in the dosage form.

14. Use of the dosage form of claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or 13 in the manufacture of a medicament for treating pain, wherein the medicament is formulated for oral administration.